sofosbuvir Articles

Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program

3 May 2013

Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting

24 April 2013

Regulatory briefs: Gilead files sofosbuvir; FDA approves Diclegis; Health Canada clears Dysport

9 April 2013

Enrollment in Gilead's ION-1 study continues following planned DSMB review

26 March 2013

Gilead rises as sofosbuvir meets endpoints in Ph III hepatitis C study

20 February 2013

Positive results from two Ph III Studies of Gilead's sofosbuvir for hepatitis C

5 February 2013

Gilead Sciences updates on hepatitis C development programs

7 January 2013

Clinical briefs from Novartis, Gilead and AstraZeneca

13 November 2012

Showing 1-8 of 8 articles

Go to beginningPrevious
  • 1
NextGo to end